Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BHV3100

            Therapeutic Area: Neurology Product Name: HTL0022562

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 23, 2021

            Details:

            The trial is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of a single ascending dose and multiple ascending doses of subcutaneous HTL0022562 in healthy adult subjects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AK1780

            Therapeutic Area: Neurology Product Name: AK1780

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $410.0 million Upfront Cash: $20.0 million

            Deal Type: Licensing Agreement January 29, 2021

            Details:

            Lilly will be responsible for future global development and regulatory activities for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HTL0018318

            Therapeutic Area: Neurology Product Name: HTL0018318

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Allergan Plc

            Deal Size: $3,290.0 million Upfront Cash: $125.0 million

            Deal Type: Terminated January 05, 2021

            Details:

            AbbVie has notified that it will be returning to Sosei Heptares all assets in development under the program including HTL0018318, all intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.